Cadila Pharmaceuticals Limited
|About IPCA Laboratory|
IPCA is an international company headquarter in Mumbai,which is one of the largest supplier of API’s in Mumbai and all over the world. IPCA produces more than 150 formulation which includes oral liquids, tablets ,dry powders and capsules. Theobromine, Acetylthiophene, and P- Bromotoluene and promotes over 36 countries of Asia, Africa, CIS, and South America, including Cambodia, Kazakhstan, Kenya, Mauritius, Myanmar, Nigeria and many more.
From 1949- 1990 It was founded in 19 OCT 1949 by a businessman and a medical professionals. In 1976 Sugar coated chloroquine marketing was started first time in india.In the 1978 IPCA launched formulation of Metoclopramide under the brand name of Perinorm. In 1980 IPCA launched the formulation of Bromhexine.In 1981 development department set up for R&D-API and R&D formulation. In 1984 first API plant was commissioned at Ratlam and second Formulations manufacturing plant commissioned at Ratlam. In 1986 first API Plant for manufacturing of Chloroquine Phosphate was set up at Ratlam ,and production of API Atenolol, started in ratlam.
from 1991-2001 In 1993 acquisition of Hoechst India’s formulations unit at Kandla.At Athal Silvassa IPCA started modern formulation plant in 1995.In 1996 IPCA commissioned API R&D Centre at Mumbai. In 1999 IPCA First time introduce the formulation of Hydroxychloroquine Sulphate under the brand name of HCQS in India. IPCA received ISO 9001 certification for Athal formulations plant.IPCA Nigeria Ltd was incorporated at Nigeria ,and acquired 'National Druggists (Pty) Ltd.' in South Africa.in 2001.
From 2002- 2012 In 2002 Wholly owned subsidiary 'Laboratories Ipca Do Brasil Ltd.' incorporated in Brazil. In 2003 IPCA also owned subsidiary in UK ltd and incorporated in United Kingdom and USA. In 2004 alliance of Innotech Pharma Limited with Ipca. In August, 2005 Ipca acquires cardiac brand Isordil from Wyeth Limited. Ipca’s new formulation plant was set up at dehradun on 5th may 2006. In 2007 Ipca enters into strategic alliance with Ranbaxy Pharmaceuticals Inc. for the U.S market. In 2008 acquisition of Tonira Pharma Ltd. through public offer. In 2010 Ratlam formulations got third position in the National Energy Conservation Award. In 2012 IDMA Quality Excellence Awards 2011 for the dehradun plant.
Zydus Cadila Healthcare Ltd.